Evaluating the efficacy of neoadjuvant endocrine therapy in HER2 low vs. HER2 negative breast cancer: An NCBD analysis

被引：0
|
作者：
Chong, Esther G.
Guo, Mengni
Castillo, Dani Ran
Bazan, Jose G.
Yap, Kelly Khai Li
Schultz-Costello, Katharine
Wu, S. Peter
机构：
[1] Loma Linda Univ, Dept Oncol Hematol, Med Ctr, Loma Linda, CA USA
[2] City Hope Natl Canc Ctr, Duarte, CA USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
599
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Evaluation of analytical accuracy of HER2 status in patients with breast cancer Comparison of HER2 GPA with HER2 IHC and HER2 FISH
    Jensen, Steffen Grann
    Thomas, Peter Engel
    Christensen, Ib Jarle
    Balslev, Eva
    Hansen, Alastair
    Hogdall, Estrid
    APMIS, 2020, 128 (11) : 573 - 582
  • [42] HER2 low and ER low breast cancer
    Schnitt, Stuart
    JOURNAL OF PATHOLOGY, 2023, 261 (SUPPL1): : S7 - S7
  • [43] Interobserver Agreement in Scoring HER2 Negative and HER2 Low Immunohistochemistry (IHC) in Breast Cancer: Reasons for discordance and efficacy of single training session
    Tseng, Yun-An
    Tamayo, Steffanie Charlyne
    Sung, C. James
    Quddus, M. Ruhul
    Hansen, Katrine
    Hanley, L. C.
    Marketkar, Shivali
    Abada, Evi
    Singh, Kamaljeet
    LABORATORY INVESTIGATION, 2023, 103 (03) : S214 - S214
  • [44] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Sasagu Kurozumi
    Mary Padilla
    Masafumi Kurosumi
    Hiroshi Matsumoto
    Kenichi Inoue
    Jun Horiguchi
    Izumi Takeyoshi
    Tetsunari Oyama
    Jim Ranger-Moore
    D. Craig Allred
    Eslie Dennis
    Hiroaki Nitta
    Breast Cancer Research and Treatment, 2016, 158 : 99 - 111
  • [45] Prognostic factors in non-metastatic HER2 'low' and HER2 'negative' breast cancer: single institute experience
    Turkel, Alper
    Dogan, Mutlu
    Sertesen, Elif
    Karacin, Cengiz
    Irkkan, Sultan cigdem
    Ates, Ozturk
    WIENER KLINISCHE WOCHENSCHRIFT, 2024, 136 (11-12) : 340 - 346
  • [46] Predictive Value of HER2 Fluorescence In Situ Hybridization (FISH) Result in HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Suo, Aili
    Zhang, Chao
    Shi, Quiying
    Wei, Zhimin
    Li, Zaibo
    Li, Xiaoxian
    MODERN PATHOLOGY, 2019, 32
  • [47] Percentage of HER2 immunohistochemistry complete membrane staining is not significantly associated with response to neoadjuvant therapy in HER2 positive breast cancer
    Li, Xiaoxian
    Zhao, Jing
    Zhang, Chao
    Li, Zaibo
    LABORATORY INVESTIGATION, 2019, 99
  • [48] Percentage of HER2 immunohistochemistry complete membrane staining is not significantly associated with response to neoadjuvant therapy in HER2 positive breast cancer
    Li, Xiaoxian
    Zhao, Jing
    Zhang, Chao
    Li, Zaibo
    MODERN PATHOLOGY, 2019, 32
  • [49] HER2 0, HER2 1+and HER2 2+/FISH Negative Breast Cancers Are Biologically Different
    Mon, Khin Su
    Zhang, Hui
    Aragao, Alessa
    Tang, Ping
    LABORATORY INVESTIGATION, 2023, 103 (03) : S182 - S183
  • [50] Predictive Value of HER2 Fluorescence In Situ Hybridization (FISH) Result in HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Suo, Aili
    Zhang, Chao
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Li, Xiaoxian
    LABORATORY INVESTIGATION, 2019, 99
12345